Who owns life technologies

For more information, please visit www. The following constitutes a "Safe Harbor" statement under the Private Securities Litigation Reform Act of This press release contains forward-looking statements that involve a number of risks and uncertainties.

Don't have an account? Create Account. Sign in Quick Order. Search Thermo Fisher Scientific. Will there be a change in the systems solution for the next-gen sequencing from AB in the new organization?

We then launched 2. SOLiD 3. With the launch of 3. As you might imagine the data output from this instrument requires a significant amount of support and bioinformatics capability. Our service organization works closely with our customers to help them sift through the data to glean the information they seek.

We have established user groups and other support systems to enable the advance of data capture, analysis, and storage. This merger brings the broad chemistry and consumables portfolio from Invitrogen and the solutions-based instrumentation portfolio of Applied Biosystems together in one organization.

There are few gaps in our combined portfolio with the possible exception of synthetic or constructive biology. But as mentioned before, we are always on the lookout for innovative technical solutions that can benefit our customers. What is to become of the skunk works going on within Invitrogen? We encourage the efforts from our colleagues at , Illumina, and Pacific Biosciences as they bring alternative technological advances to the marketplace. What is the plan to move from the offering of solutions in the life science market to the offering of solutions or products in the clinic?

There is still a lot of work and research to be done at the genomics level, and we just received FDA k clearance for a new real-time PCR instrument for use with new flu test from CDC. I personally think that the future of molecular diagnostics and disease state focus will require the validation and verification of protein biomarkers as well. Translational medicine, the understanding of the disease state at the molecular level, will focus on the early diagnosis and prevention of disease.

Personalized medicine, though based on the underlying genomic makeup, will be monitored and treated at the level of the protein in many cases. Our investment in mass spec supports the view that this is where the battle will be won. Important information. More about Life Technologies. More news by Life Technologies. Top Companies. Topics A-Z. All topics. About bionity.

Life Technologies acquired certain assets of Telios Pharmaceuticals, Inc. The company blamed uncertainties about health care reform and the possibility of price controls on drugs for the sales slowdown and also cited adverse currency exchange rates on foreign sales.

During the year Adler, no longer board chairman but still a director and investor, was named to the annual list of the Top "Molecular Millionaires" published by Genetic Engineering News.

During Life Technologies took full control of a joint venture laboratory it maintained with Protogene Laboratories Inc. Previously, Protogene had owned 75 percent of the venture.

Life Technologies also established wholly owned subsidiaries in Italy and Spain during and bought a majority stake in a joint venture that it had operated in Japan with Tokyo-based Oriental Yeast Co. In February it purchased Custom Primers, a manufacturer of custom oligonucleotides sold to researchers in gene sequencing and other clinical studies. Plans called for the complex to be completed around the end of The company had been leasing space in five spread-out buildings in a Gaithersburg office park a few miles from Interstate , Maryland's "technology corridor.

Among Life Technologies' customers in was the nation's second largest biotech company, Genentech Inc. Japan, Europe, and Southeast Asia were areas of major overseas business. In November Adler held , shares of the All officers and directors of the companies held a combined , shares. Stark Thompson had been the company's president and chief executive officer since Production facilities were operating at about 85 percent of capacity during the year.